National surveillance data find that more than one-fourth of preschoolers aged 2 to 5 years are now overweight or obese.
FDA extends approval of Evkeeza for homozygous familial hypercholesterolemia in young children
March 22nd 2023Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor indicated for patients as young at 5 years to control high levels of low-density lipoprotein cholesterol (LDL-C) as a result of HoFH.
2 Clarke Drive
Cranbury, NJ 08512